Loading...

New Strategies for Treatment of ALK Rearranged Non-Small Cell Lung Cancers

The identification of oncogenic alterations in subsets of non-small cell lung cancers (NSCLC) is transforming clinical care. Genomic rearrangements in the anaplastic lymphoma kinase (ALK) are detected in 3 to 7% of NSCLC patients. The ALK tyrosine kinase inhibitor crizotinib has demonstrated clinica...

Full description

Saved in:
Bibliographic Details
Main Authors: Sasaki, Takaaki, Jänne, Pasi A.
Format: Artigo
Language:Inglês
Published: 2011
Subjects:
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3477548/
https://ncbi.nlm.nih.gov/pubmed/22010214
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-11-1404
Tags: Add Tag
No Tags, Be the first to tag this record!